Indication
This vaccine is indicated for active immunisation against hepatitis B virus infection in non-immune adults (>=18 years). The specific at risk categories to be immunised are to be determined on the basis of official recommendations.
Loading your page…
Hepatitis B;Immunization
Marketing Authorisation Holder: Evans Vaccines Ltd.
EMA Authorisation: 04/08/2000
INN: hepatitis B surface antigens recombinant (S, pre-S1, pre-S2) adsorbed on aluminium hydroxide [produced on genetically engineered murine (C127I) cells]
AI Drug & Interaction Analysis
Free account required
Ask Osler about Hepacare: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.